33 results on '"Lafayette, Richard"'
Search Results
2. A Focus Group Study of Self-Management in Patients With Glomerular Disease
3. Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy
4. Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy
5. Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis
6. Persistent Disease Activity in Patients With Long-Standing Glomerular Disease
7. WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN
8. WCN24-1688 SELF-REPORTED QUALITY OF LIFE IN COMPLEMENT 3 GLOMERULOPATHY PATIENTS DELINEATED BY CKD STAGE: A REAL-WORLD, MULTI-COUNTRY SURVEY
9. WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY
10. WCN24-1163 TREATMENT GOALS FROM THE PERSPECTIVE OF IMMUNOGLOBULIN A NEPHROPATHY PATIENTS - RESULTS FROM A REAL-WORLD STUDY
11. WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL
12. WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
13. WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY
14. WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
15. WCN24-1680 PREVALENCE AND CLINICAL CHARACTERISTICS OF KIDNEY TRANSPLANTS IN COMPLEMENT 3 GLOMERULOPATHY PATIENTS: RESULTS FROM A REAL-WORLD, MULTI-COUNTRY SURVEY
16. WCN24-1159 TREATMENT PATTERNS IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY - EVIDENCE FROM REAL-WORLD DATA
17. WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
18. WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19
19. WCN24-1158 REAL-WORLD ANALYSIS OF PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY – DIAGNOSIS AND DISEASE MONITORING
20. WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY
21. WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
22. Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
23. Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study
24. NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome
25. One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy
26. International Physicians Delphi Survey: Managing Patients With IgA Nephropathy
27. A Focus Group Study of Self-Management in Patients With Glomerular Disease
28. Why Target the Gut to Treat IgA Nephropathy?
29. Persistent Disease Activity in Patients With Long-Standing Glomerular Disease
30. An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression
31. Increasing Options for First-Line Therapy in Primary FSGS?
32. Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study
33. An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.